Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes

Venkata S. Sabbisetti, Sushrut S. Waikar, Daniel J. Antoine, Adam Smiles, Chang Wang, Abinaya Ravisankar, Kazumi Ito, Sahil Sharma, Swetha Ramadesikan, Michelle Lee, Briskin, Philip L. De Jager, Thanh Thu Ngo, Mark Radlinski, James W. Dear, Kevin B. Park, Rebecca Betensky, Andrzej S. Krolewski, Joseph V. Bonventre

Research output: Contribution to journalArticle

Abstract

Currently, no blood biomarker that specifically indicates injury to the proximal tubule of the kidney has been identified. Kidney injury molecule-1 (KIM-1) is highly upregulated in proximal tubular cells following kidney injury. The ectodomain of KIM-1 is shed into the lumen, and serves as a urinary biomarker of kidney injury. We report that shed KIM-1 also serves as a blood biomarker of kidney injury. Sensitive assays to measure plasma and serum KIM-1 in mice, rats, and humans were developed and validated in the current study. Plasma KIM-1 levels increased with increasing periods of ischemia (10, 20, or 30 minutes) in mice, as early as 3 hours after reperfusion; after unilateral ureteral obstruction (day 7) in mice; and after gentamicin treatment (50 or 200 mg/kg for 10 days) in rats. In humans, plasma KIM-1 levels were higher in patients with AKI than in healthy controls or post-cardiac surgery patients without AKI (area under the curve, 0.96). In patients undergoing cardiopulmonary bypass, plasma KIM-1 levels increased within 2 days after surgery only in patients who developed AKI (P<0.01). Blood KIM-1 levels were also elevated in patients with CKD of varous etiologies. In a cohort of patients with type 1 diabetes and proteinuria, serum KIM-1 level at baseline strongly predicted rate of eGFR loss and risk of ESRD during 5-15 years of follow-up, after adjustment for baseline urinary albumin-to-creatinine ratio, eGFR, and Hb1Ac. These results identify KIM-1 as a blood biomarker that specifically reflects acute and chronic kidney injury.

Original languageEnglish (US)
Pages (from-to)2177-2186
Number of pages10
JournalJournal of the American Society of Nephrology
Volume25
Issue number10
DOIs
StatePublished - Jan 1 2014

Fingerprint

Type 1 Diabetes Mellitus
Acute Kidney Injury
Chronic Kidney Failure
Biomarkers
Kidney
Wounds and Injuries
Ureteral Obstruction
Proximal Kidney Tubule
Gentamicins
Serum
Cardiopulmonary Bypass
Ambulatory Surgical Procedures
Proteinuria
Thoracic Surgery
Reperfusion
Area Under Curve
Albumins
Creatinine
Ischemia

ASJC Scopus subject areas

  • Nephrology

Cite this

Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. / Sabbisetti, Venkata S.; Waikar, Sushrut S.; Antoine, Daniel J.; Smiles, Adam; Wang, Chang; Ravisankar, Abinaya; Ito, Kazumi; Sharma, Sahil; Ramadesikan, Swetha; Lee, Michelle; Briskin; De Jager, Philip L.; Ngo, Thanh Thu; Radlinski, Mark; Dear, James W.; Park, Kevin B.; Betensky, Rebecca; Krolewski, Andrzej S.; Bonventre, Joseph V.

In: Journal of the American Society of Nephrology, Vol. 25, No. 10, 01.01.2014, p. 2177-2186.

Research output: Contribution to journalArticle

Sabbisetti, VS, Waikar, SS, Antoine, DJ, Smiles, A, Wang, C, Ravisankar, A, Ito, K, Sharma, S, Ramadesikan, S, Lee, M, Briskin, De Jager, PL, Ngo, TT, Radlinski, M, Dear, JW, Park, KB, Betensky, R, Krolewski, AS & Bonventre, JV 2014, 'Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes', Journal of the American Society of Nephrology, vol. 25, no. 10, pp. 2177-2186. https://doi.org/10.1681/ASN.2013070758
Sabbisetti, Venkata S. ; Waikar, Sushrut S. ; Antoine, Daniel J. ; Smiles, Adam ; Wang, Chang ; Ravisankar, Abinaya ; Ito, Kazumi ; Sharma, Sahil ; Ramadesikan, Swetha ; Lee, Michelle ; Briskin ; De Jager, Philip L. ; Ngo, Thanh Thu ; Radlinski, Mark ; Dear, James W. ; Park, Kevin B. ; Betensky, Rebecca ; Krolewski, Andrzej S. ; Bonventre, Joseph V. / Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. In: Journal of the American Society of Nephrology. 2014 ; Vol. 25, No. 10. pp. 2177-2186.
@article{f05e227f8bac4e39afdb471abf7c034f,
title = "Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes",
abstract = "Currently, no blood biomarker that specifically indicates injury to the proximal tubule of the kidney has been identified. Kidney injury molecule-1 (KIM-1) is highly upregulated in proximal tubular cells following kidney injury. The ectodomain of KIM-1 is shed into the lumen, and serves as a urinary biomarker of kidney injury. We report that shed KIM-1 also serves as a blood biomarker of kidney injury. Sensitive assays to measure plasma and serum KIM-1 in mice, rats, and humans were developed and validated in the current study. Plasma KIM-1 levels increased with increasing periods of ischemia (10, 20, or 30 minutes) in mice, as early as 3 hours after reperfusion; after unilateral ureteral obstruction (day 7) in mice; and after gentamicin treatment (50 or 200 mg/kg for 10 days) in rats. In humans, plasma KIM-1 levels were higher in patients with AKI than in healthy controls or post-cardiac surgery patients without AKI (area under the curve, 0.96). In patients undergoing cardiopulmonary bypass, plasma KIM-1 levels increased within 2 days after surgery only in patients who developed AKI (P<0.01). Blood KIM-1 levels were also elevated in patients with CKD of varous etiologies. In a cohort of patients with type 1 diabetes and proteinuria, serum KIM-1 level at baseline strongly predicted rate of eGFR loss and risk of ESRD during 5-15 years of follow-up, after adjustment for baseline urinary albumin-to-creatinine ratio, eGFR, and Hb1Ac. These results identify KIM-1 as a blood biomarker that specifically reflects acute and chronic kidney injury.",
author = "Sabbisetti, {Venkata S.} and Waikar, {Sushrut S.} and Antoine, {Daniel J.} and Adam Smiles and Chang Wang and Abinaya Ravisankar and Kazumi Ito and Sahil Sharma and Swetha Ramadesikan and Michelle Lee and Briskin and {De Jager}, {Philip L.} and Ngo, {Thanh Thu} and Mark Radlinski and Dear, {James W.} and Park, {Kevin B.} and Rebecca Betensky and Krolewski, {Andrzej S.} and Bonventre, {Joseph V.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1681/ASN.2013070758",
language = "English (US)",
volume = "25",
pages = "2177--2186",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "10",

}

TY - JOUR

T1 - Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes

AU - Sabbisetti, Venkata S.

AU - Waikar, Sushrut S.

AU - Antoine, Daniel J.

AU - Smiles, Adam

AU - Wang, Chang

AU - Ravisankar, Abinaya

AU - Ito, Kazumi

AU - Sharma, Sahil

AU - Ramadesikan, Swetha

AU - Lee, Michelle

AU - Briskin,

AU - De Jager, Philip L.

AU - Ngo, Thanh Thu

AU - Radlinski, Mark

AU - Dear, James W.

AU - Park, Kevin B.

AU - Betensky, Rebecca

AU - Krolewski, Andrzej S.

AU - Bonventre, Joseph V.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Currently, no blood biomarker that specifically indicates injury to the proximal tubule of the kidney has been identified. Kidney injury molecule-1 (KIM-1) is highly upregulated in proximal tubular cells following kidney injury. The ectodomain of KIM-1 is shed into the lumen, and serves as a urinary biomarker of kidney injury. We report that shed KIM-1 also serves as a blood biomarker of kidney injury. Sensitive assays to measure plasma and serum KIM-1 in mice, rats, and humans were developed and validated in the current study. Plasma KIM-1 levels increased with increasing periods of ischemia (10, 20, or 30 minutes) in mice, as early as 3 hours after reperfusion; after unilateral ureteral obstruction (day 7) in mice; and after gentamicin treatment (50 or 200 mg/kg for 10 days) in rats. In humans, plasma KIM-1 levels were higher in patients with AKI than in healthy controls or post-cardiac surgery patients without AKI (area under the curve, 0.96). In patients undergoing cardiopulmonary bypass, plasma KIM-1 levels increased within 2 days after surgery only in patients who developed AKI (P<0.01). Blood KIM-1 levels were also elevated in patients with CKD of varous etiologies. In a cohort of patients with type 1 diabetes and proteinuria, serum KIM-1 level at baseline strongly predicted rate of eGFR loss and risk of ESRD during 5-15 years of follow-up, after adjustment for baseline urinary albumin-to-creatinine ratio, eGFR, and Hb1Ac. These results identify KIM-1 as a blood biomarker that specifically reflects acute and chronic kidney injury.

AB - Currently, no blood biomarker that specifically indicates injury to the proximal tubule of the kidney has been identified. Kidney injury molecule-1 (KIM-1) is highly upregulated in proximal tubular cells following kidney injury. The ectodomain of KIM-1 is shed into the lumen, and serves as a urinary biomarker of kidney injury. We report that shed KIM-1 also serves as a blood biomarker of kidney injury. Sensitive assays to measure plasma and serum KIM-1 in mice, rats, and humans were developed and validated in the current study. Plasma KIM-1 levels increased with increasing periods of ischemia (10, 20, or 30 minutes) in mice, as early as 3 hours after reperfusion; after unilateral ureteral obstruction (day 7) in mice; and after gentamicin treatment (50 or 200 mg/kg for 10 days) in rats. In humans, plasma KIM-1 levels were higher in patients with AKI than in healthy controls or post-cardiac surgery patients without AKI (area under the curve, 0.96). In patients undergoing cardiopulmonary bypass, plasma KIM-1 levels increased within 2 days after surgery only in patients who developed AKI (P<0.01). Blood KIM-1 levels were also elevated in patients with CKD of varous etiologies. In a cohort of patients with type 1 diabetes and proteinuria, serum KIM-1 level at baseline strongly predicted rate of eGFR loss and risk of ESRD during 5-15 years of follow-up, after adjustment for baseline urinary albumin-to-creatinine ratio, eGFR, and Hb1Ac. These results identify KIM-1 as a blood biomarker that specifically reflects acute and chronic kidney injury.

UR - http://www.scopus.com/inward/record.url?scp=84908075907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908075907&partnerID=8YFLogxK

U2 - 10.1681/ASN.2013070758

DO - 10.1681/ASN.2013070758

M3 - Article

C2 - 24904085

AN - SCOPUS:84908075907

VL - 25

SP - 2177

EP - 2186

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 10

ER -